Drug Discovery Services

• Technology for evaluating drug efficacy, ADME, and safety using human iPSC-derived cells
• AI technology that implements precise data analysis and proposes new possibilities
• Long time experience in research and development of therapeutics for infectious diseases and oncology
• Broad range of capabilities in antibodies, peptides, LNPs, exosomes, etc.

We support discovery research with a variety of cutting-edge technologies.

We offer various assay services utilizing human iPSC-derived cell products from FUJIFILM Cellular Dynamics, Inc., a global prominent provider of iPSC derived cells, and iPSC -derived intestinal epithelial cells (F-hiSIEC™) developed by Fujifilm.
We provide cardiotoxicity risk assessment services based on our experience and technology that have contributed to the prevalence of evaluation methods in a research consortium. Furthermore, we support our clients' drug discovery efforts by offering evaluation services that are more precise than standard hERG tests, achieved at high throughput.
We are also experts in neural disease and neuroinflammation model assays, intestinal permeability assay, and BBB permeability assays, complex cell culture system.
With our flexible proposals to meet customer needs, our tailor-made and research-accellerated services go beyond routine studies.

We provide drug2drugs®, a service for converting small molecules and peptides into active compounds by combining AAM descriptors (Amino-Acid Mapping), which simulate the interaction between compounds and proteins, with structure generation AI. drug2drugs® requires only structural information of the active compound and does not require information on the target protein. This is a new approach to the conversion of small molecules and peptides to other scaffold.

The COVID-19 pandemic  has reaffirmed the importance of drug discovery against infectious diseases.
The overcoming of not only the pandemic but also AMR (AMR: Anti-Microbial Resistance) and other significant infectious diseases such as HIV/AIDS, tuberculosis, and malaria has become an extremely important public health issue.
We believe that our highly specialized bioassessment service, which utilizes pathogenic microorganisms and draws on Fujifilm Toyama Chemical's extensive experience in infectious disease research, can assist you in your drug discovery research aimed at solving public health issues.

We provide antibody discovery services using the DNA immunization method, in which DNA corresponding to the amino acid sequence of an antigen is injected and the antigen is expressed in the animal body for immunization. Compared to conventional methods that use proteins or peptides as antigens, this method has the potential to produce antibodies with higher affinity for multiple transmembrane proteins, which have been difficult to produce. Combined with our proprietary rabbit monoclonal antibody production technology using B-cell screening, we are able to obtain antibodies with “high functionality x high affinity”.

We provide discovery service for peptides, which are attracting attention for various applications including middle molecule drugs. mRNA display-based screening methods enable to obtain hit peptides that bind tightly to target proteins from large libraries of macrocyclic peptides containing non-natural amino acids. Additionally, we offer chemical synthesis of peptides and a variety of bioassays to facilitate customer's approach to peptide drug discovery.